M&A M&A
Drug maker Lupin acquires 3 anti-diabetes trademarks from Germany’s Boehringer Ingelheim
Source Boehringer Ingelheim International GmbH (opens in a new tab)Press Release (opens in a new tab)
Listed drug maker Lupin Ltd has acquired anti-diabetes trademarks Gibtulio, Gibtulio Met and Ajaduo from Boehringer Ingelheim International GmbH (Boehringer Ingelheim). The trademark rights for these brands will be transferred to Lupin by March next year.Lupin has been marketing Gibtulio and Gibtulio Met since 2016 and Ajaduo since 2018, in India, through a co-marketing agreement with Boehringer Ingelheim India.The acquired trademarks belong to a class of oral anti-diabetic drug called sodium glucose co-transporter-2 (SGLT-2) inhibitor (and combinations). These are meant to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.